Overview
- AIM's patent covers using Ampligen with anti-PD-1/PD-L1 checkpoint inhibitors across multiple cancers, including pancreatic cancer.
- Shares jumped about 97% on the announcement, with trading volume spiking to roughly 10.6 million versus a three-month average near 2.7 million.
- The Japanese approval adds to existing patents in the United States expiring August 9, 2039, and the Netherlands expiring December 19, 2039.
- The company plans to seek orphan drug designation in Japan for Ampligen in pancreatic cancer, building on orphan status already granted in the U.S. and EU.
- Despite the IP win, independent reporting highlights weak finances and limited regulatory approvals for Ampligen, which is authorized only in Argentina for severe chronic fatigue syndrome.